Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALVOEYE-D AVT06 PFS Handling and Safety in Chorioretinal Vascular Disease
2023-505225-13-00Phase 3Completed
- Sponsor
- Alvotech
- Start
- Nov 2023
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 3, open-label, single-arm trial of AVT06 in chorioretinal vascular disease (not a recognized single disease entity), exudative macular degeneration, diabetic macular edema (DME) and 3 more, sponsored by Alvotech. Primary endpoints: Proportion of AVT06 injections successfully administered with pre-filled syringe at Day 1, Incidence of ocular treatment-emergent adverse events associated with the study eye and 2 more. Started Nov 2023; status: completed.
02
Drugs
AVT06
03
Conditions
chorioretinal vascular disease (not a recognized single disease entity)exudative macular degenerationdiabetic macular edema (DME)myopic choroidal neovascularisation (mCNV)Vein occlusion (RVO)
Beyond the preview
Go deeper on 2023-505225-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505225-13-00.